# Flamingo Therapeutics NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flamingo-therapeutics

- Industry: Biotechnology
- Headquarters: Leuven, Belgium
- Website: www.flamingotx.com
- Latest round: Series A (Jul 1, 2021)
- Investors on record: 2

## About

Based in Belgium, and founded in 2020, Flamingo Therapeutics NV operates as an RNA (ribonucleic acid) therapeutics company. The company was founded by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners, and PMV. In March 2023, Dynacure SA, a portfolio company of Andera Partners, CDC Enterprises, Perceptive Advisors, and Tekla Capital Management, agreed to merge with Flamingo Therapeutics and will continue to operate under the Flamingo Therapeutics brand. As of 2023, the company’s president and CEO is Stéphane van Rooijen.

Flamingo Therapeutics offers a drug development platform, which is a biotech platform that develops RNA-based therapeutics for cancer patients. The company’s pipeline programs include Danvatirsen, a drug that targets STAT-3, and FTX-001, a drug that targets MALAT1. In addition, the company provides FLAME (Flamingo LncRNA Antisense Mining Engine), which is a long non-coding RNA platform that develops drugs for diseases like cancer.

## Funding rounds

- Series A, Jul 1, 2021 — PMV, Kurma Partners

## Investors

- PMV (https://capitalatlas.ai/funds/pmv) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A